Yüklüyor......
Alemtuzumab in refractory Sézary syndrome
Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promis...
Kaydedildi:
| Yayımlandı: | An Bras Dermatol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Sociedade Brasileira de Dermatologia
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5087225/ https://ncbi.nlm.nih.gov/pubmed/27828640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/abd1806-4841.20164322 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|